SecBot SecBot
EFFECT ·Filed Aug 28, 2026

ORKA

Oruka Therapeutics, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed2mo ago SEC9999999995-26-002787
IPO/offering going effective
Actionable Insight ▼ Bearish

The effective shelf registration introduces a persistent dilution overhang. Monitor for any takedown announcements or prospectus supplements that would signal an imminent offering. The stock may face downward pressure as the market prices in the increased flexibility for capital raising.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$91.15
T+0 close · Aug 28, 2026 · via day close
Latest settled
−7.63%
T+20 · $84.19 · next T+60 in 6d
Vs SPY
−7.89%
α at T+20
Latest observation
+42.17%
T+54 · FF3 residual α
  1. T+0 · Aug 28 $91.15entry
  2. T+1 · 3mo ago +1.62%α +1.92% · $92.62
  3. T+5 · 2mo ago +1.50%α +1.39% · $92.51
  4. T+20 · 7w ago −7.63%α −7.89% · $84.19
  5. T+55 · todayOpen
  6. T+60 · in 6d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Oruka Therapeutics' S-3 shelf registration (File No. 333-298488) became effective on August 27, 2026. This allows the company to sell securities at any time, creating potential dilution overhang. The effectiveness follows a prior S-3 filed in April 2026, and the cross-filing actuarial verdict confirms this is an amplifier, the shelf context amplifies the impact of the IPO context, meaning the market should price in the increased flexibility for capital raising.

Key Facts

  • S-3 shelf registration became effective on August 27, 2026
  • File No. 333-298488
  • Company can now sell securities at any time, creating dilution risk
  • Cross-filing actuarial verdict confirms this is an amplifier, shelf context amplifies IPO context

Financial Impact

Potential dilution from future offerings, no specific amount disclosed

dilution

Risk Factors

  • Dilution from future offerings
  • Market may price in overhang, pressuring stock
  • No specific offering terms disclosed, uncertainty around timing and size

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-002787
Document: 9999999995-26-002787-index.html9999999995-26-002787
Document: 9999999995-26-002787.txt9999999995-26-002787

Track record

40 reports on ORKA

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 10 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry price pending
  3. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
  4. Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
  5. Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
  6. Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
  7. Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
  8. Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
  9. Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
  10. Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
Showing 10 of 40

US Market Status

Market Closed · Opens Wed (11h 36m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 28, 2026